Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

VTV Therapeutics Inc (VTVT) USD0.01 A

Sell:$1.38 Buy:$1.47 Change: $0.02 (1.40%)
NASDAQ:0.83%
Market closed |  Prices as at close on 18 October 2019 | Switch to live prices |
Sell:$1.38
Buy:$1.47
Change: $0.02 (1.40%)
Market closed |  Prices as at close on 18 October 2019 | Switch to live prices |
Sell:$1.38
Buy:$1.47
Change: $0.02 (1.40%)
Market closed |  Prices as at close on 18 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Contact details

Address:
4170 Mendenhall Oaks Pkwy
HIGH POINT
27265-8345
United States
Telephone:
+1 (336) 8410300
Website:
vtvtherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VTVT
ISIN:
US9183851057
Market cap:
$76.33 million
Shares in issue:
54.13 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Jeffrey Kindler
    Executive Chairman of the Board
  • Stephen Holcombe
    President, Chief Executive Officer
  • Rudy Howard
    Chief Financial Officer, Executive Vice President

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.